Announcement on Progress in Drug Marketing Authorization Transfer
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Progress in Drug Marketing Authorization Transfer
Filed with SSE · · 4 pages · Chinese
Release
Hunan Fangsheng Pharmaceutical Co., Ltd. on 6ix
Earlier from Hunan Fangsheng Pharmaceutical
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Proposed Inclusion of Company Products in the Centralized Volume Procurement of National Chinese Patent Medicine Procurement Alliance
- Announcement on Obtaining Summary Report of Phase III Clinical Trial for Pediatric Jingxing Anti-tussive Granules in Adults with Acute Tracheobronchitis (Syndrome of Wind-cold Transformation into Heat)
Later from Hunan Fangsheng Pharmaceutical
- Announcement on Resolutions of the 2nd Extraordinary Meeting of the 6th Board of Directors in 2026
- Announcement on Progress in Transferring Partial Equity of Holding Subsidiaries and Introducing Strategic Investors
- Announcement on Progress in the Sale of Partial Equity in Investment Projects by the M&A Fund Participated in and Established by the Company
- Announcement on Proposed Withdrawal from an M&A Fund and Related Party Transactions
- Announcement on Change of "Drug Manufacturing License"
Follow Hunan Fangsheng Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Fangsheng Pharmaceutical